9月8日 - ** 药物开发商Rapport Therapeutics RAPP.O的股价盘前翻了一番多，达到30美元
** RAPP的实验性口服药物RAP-219在一项针对难以治疗的局灶性癫痫发作成人患者的中期试验中对30名患者进行了 (link)，试验中植入了一个脑设备以跟踪癫痫发作活动。
** 该公司称，经过为期八周的治疗，患者的癫痫发作次数中位数下降了77.8%，24%的患者摆脱了癫痫发作。
** Rapport公司表示，计划在今年晚些时候与美国监管机构会面，并在2026年第三季度启动两项后期研究。
** 截至上一交易日收盘，RAPP股价年累计下跌19.5%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.